GLOW for veterinarians

Overview

GLOW is the integumentary regeneration protocol. Three peptides targeting the skin and coat from three angles. GHK-Cu drives collagen and elastin synthesis in fibroblasts. BPC-157 drives angiogenesis and re-epithelialization at wound margins. TB-500 drives cell migration and endothelial repair.

The goal is coat quality, skin turgor, scar remodeling, and chronic dermatologic improvement.

Mechanism of action

01GHK-Cu shifts the expression of genes tied to dermal repair and remodeling.
02BPC-157 accelerates re-epithelialization at wound and inflammation sites.
03TB-500 drives cell migration and cytoskeletal remodeling in dermal fibroblasts.
04Combined action addresses collagen synthesis, vascularization, and cell migration in one protocol.
05Delivered as a subcutaneous injection.

Molecular data

ComponentDetail

GHK-CuCopper tripeptide

BPC-157Pentadecapeptide

TB-500Thymosin beta-4 fragment

RouteSubcutaneous injection

Species

Dog

Chronic atopic dermatitis. Post-surgical scar remodeling. Coat quality in aging dogs. Chronic hot spots refractory to conventional therapy.

Prescribing indications

DermatologicSupportedChronic dermatologic conditions.
RecoverySupportedPost-surgical wound and scar support.

Dosing and administration

Starting, maintenance, and loading doses are calculated in the platform for the patient’s weight band, at the vial strength our compounding partner dispenses, and drawn to U-100 syringe units for the client’s dosing card. Any override is logged with your initials.

See the worked dose example

Screening and safety

Screen first

Copper storage breeds, history of neoplasia

Follow up

Wound size or lesion photos at baseline and recheck. Measure at baseline and recheck at 4 to 6 weeks with the same measure.

References

See the GHK-Cu and BPC-157 monographs. The combination evidence rests on the additive mechanisms of all three components.GHK-Cu BPC-157 monograph and evidence library.BPC-157 Goldstein AL et al. Thymosin beta-4: multi-functional regenerative peptide. Expert Opinion on Biological Therapy.PubMed

GHK-Cu

Dermatologic

BPC-157

Recovery

Wolverine

Blend. Recovery

Dispensed only as a patient-specific compounded prescription under FDA GFI 256.

This monograph describes a compounded veterinary medication available by prescription only through a licensed veterinarian inside an active veterinarian-client-patient relationship. Not FDA-approved for animal or human use. Compounded on a patient-specific basis under FDA Guidance for Industry #256. For educational use by licensed veterinarians. Not intended for consumer self-prescribing.

GLOW